Alpha-Synuclein and Mitochondria Form Toxic Partnership in Parkinson's Disease

Parkinson's disease involves two key pathological features that may work together to destroy brain cells: alpha-synuclein protein aggregates called Lewy bodies and mitochondrial dysfunction. This comprehensive review from Van Andel Institute researchers examines how these seemingly separate problems interact to drive neurodegeneration.

The authors analyzed current research showing that alpha-synuclein, normally involved in neurotransmitter release, becomes toxic when it misfolds and clumps together. Simultaneously, mitochondria—the cellular powerhouses that produce energy—begin failing in Parkinson's patients. Recent studies reveal these processes are interconnected: dysfunctional mitochondria become sequestered within Lewy bodies, while alpha-synuclein directly impairs mitochondrial function.

This creates a destructive feedback loop. As alpha-synuclein accumulates, it damages mitochondria, reducing cellular energy production. Damaged mitochondria then become trapped in protein aggregates, further compromising cell function. The researchers propose that mitochondrial dysfunction may be a final common pathway to cell death, regardless of whether Parkinson's is caused by genetic mutations or environmental toxins.

These findings suggest new therapeutic approaches targeting both protein aggregation and mitochondrial health simultaneously. Rather than addressing each problem separately, treatments could focus on breaking the toxic cycle between alpha-synuclein and mitochondrial dysfunction. This integrated understanding may lead to more effective disease-modifying therapies that slow or halt Parkinson's progression.